ImmunoGen Announces Departure of Anna Berkenblit, Chief Medical Officer
31 Julho 2023 - 7:35AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Anna Berkenblit, MD, Senior Vice President and
Chief Medical Officer, is stepping down from her position with the
Company to take a well-deserved professional hiatus prior to
pursuing new opportunities outside of ImmunoGen. Dr. Berkenblit
will continue with the Company through the end of August to support
the transition of her responsibilities. Michael Vasconcelles, MD,
Executive Vice President, Research, Development, and Medical
Affairs, will assume the role of Chief Medical Officer.
"Over the last eight years, Anna has played an essential role in
the transformation of ImmunoGen," said Mark Enyedy, ImmunoGen's
President and Chief Executive Officer. "First and foremost, she led
the design and execution of the pivotal development program for
ELAHERE® (mirvetuximab soravtansine-gynx) that culminated in
FDA-accelerated approval late last year in folate receptor alpha
positive platinum-resistant ovarian cancer and the unprecedented
survival data reported at ASCO in June that have transformed the
treatment landscape for patients with this disease. Under her
leadership, we have also advanced our broader clinical pipeline of
next-generation ADCs, with top-line data from our second pivotal
program expected next year. In parallel, she has built and leaves
us with a highly talented development organization that has
cultivated deep relationships with thought leaders around the world
and can rapidly deliver complex studies with high-quality data.
Finally, she has been a valued colleague to me and the rest of the
ImmunoGen Executive Committee. I wish Anna the very best in her
future endeavors and offer my thanks for her unrelenting work on
behalf of ImmunoGen, our collaborators, and most importantly,
patients in need of more good days."
"I take immense pride in having been a part of the leadership
team that led ImmunoGen to success with SORAYA and MIRASOL, built a
clinical development team filled with top talent capable of
operating effectively during a global pandemic, and contributed to
the efforts that brought ELAHERE through to accelerated approval
for patients with platinum-resistant ovarian cancer," said Anna
Berkenblit, MD, Senior Vice President and Chief Medical Officer of
ImmunoGen. "It has been a pleasure and a privilege to serve this
organization. As I look ahead to what's next, I look forward to
spending time with my family, continuing board work with other
companies, and pursuing consulting in the coming months while I
watch ImmunoGen's bright future unfold."
ABOUT IMMUNOGEN ImmunoGen is developing the next
generation of antibody-drug conjugates (ADCs) to improve outcomes
for cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
FORWARD-LOOKING STATEMENTS This press release
includes forward-looking statements. These statements include, but
are not limited to, ImmunoGen's expectations related to the
potential of ELAHERE to change how ovarian cancer is treated and
the Company's business and product development strategies. A range
of factors could cause ImmunoGen's actual results to differ
materially from those discussed or implied in the forward-looking
statements, and you are cautioned not to place undue reliance on
these forward-looking statements, which are current only as of the
date of this release. Factors that could cause future results to
differ materially from such expectations include, but are not
limited to: top-line data may change as more patient data become
available and are subject to audit and verification procedures; the
timing and outcome of the Company's preclinical and clinical
development processes; the results of the ongoing MIRASOL trial may
not support full approval of ELAHERE and, if so, additional studies
may be required; the difficulties inherent in the development of
novel pharmaceuticals, including uncertainties as to the timing,
expense, and results of preclinical studies, clinical trials, and
regulatory processes; the timing and outcome of the Company's
anticipated interactions with regulatory authorities; the risk that
the Company may not be able to obtain adequate price and
reimbursement for any approved products, including the potential
for delays or additional difficulties for ELAHERE in light of the
FDA granting accelerated approval; risks and uncertainties
associated with the scale and duration of the COVID-19 pandemic and
the resulting impact on ImmunoGen's industry and business; and
other factors as set forth in the Company's Annual Report on Form
10-K filed with the Securities and Exchange Commission on March 1,
2023, the Company's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on April 28, 2023, and other
reports filed with the Securities and Exchange Commission. The
forward-looking statements in this press release speak only as of
the date of this press release. ImmunoGen undertakes no obligation
to update any forward-looking statement, whether as a result of
latest information, future developments, or otherwise, except as
may be required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230731911898/en/
INVESTOR RELATIONS ImmunoGen Anabel Chan
781-895-0600 anabel.chan@immunogen.com
MEDIA ImmunoGen Courtney O'Konek
781-895-0600 courtney.okonek@immunogen.com
OR
FTI Consulting Robert Stanislaro 212-850-5657
robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
ImmunoGen (NASDAQ:IMGN)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024